James R. Berenson, MD, Inc., West Hollywood, CA, 90069, USA.
Oncotherapeutics, , West Hollywood, CA, 90069, USA.
Ann Hematol. 2021 Apr;100(4):1079-1085. doi: 10.1007/s00277-020-04351-5. Epub 2020 Nov 25.
The purpose of this single-center retrospective study was to determine the incidence of decreased blood phosphorus levels and hypophosphatemia among multiple myeloma (MM) patients treated with elotuzumab. Hypophosphatemia, which is defined as a serum phosphorus concentration < 2.5 mg/dL, leads to complications ranging from muscle weakness and disorientation to seizures and heart failure. A total of 23 MM patients receiving care in a clinic specializing in treatment of MM from July 2018 to March 2020 and treated with an elotuzumab-containing therapy were evaluated, and 9 were investigated for this study. Elotuzumab was given at 10 mg/kg weekly for the first two treatment cycles (28 days/cycle), followed by 10 mg/kg every other week for all subsequent cycles. Four different elotuzumab combination therapies were administered: 1) elotuzumab and dexamethasone 2) elotuzumab, lenalidomide and dexamethasone 3) elotuzumab, pomalidomide and dexamethasone and 4) elotuzumab, carfilzomib, pomalidomide, and dexamethasone. Phosphorous levels were determined at a median of every 13 days at intervals ranging from once weekly to once monthly until a phosphate supplement was prescribed to the patient or when elotuzumab treatment was discontinued. We found that regardless of elotuzumab combination therapy, all patients treated showed decreased phosphorus levels after initiating elotuzumab treatment with reductions ranging from 12.5% to 44.1% below baseline. Six participants (67%) demonstrated an average serum phosphorus at or below 2.5 mg/dL after starting elotuzumab therapy. This retrospective study suggests that hypophosphatemia commonly occurs among MM patients receiving elotuzumab-containing therapies.
这项单中心回顾性研究的目的是确定接受依鲁替尼治疗的多发性骨髓瘤（MM）患者中血磷水平降低和低磷血症的发生率。低磷血症定义为血清磷浓度<2.5mg/dL，可导致从肌肉无力和定向障碍到癫痫发作和心力衰竭等多种并发症。本研究共评估了 23 名在专门治疗 MM 的诊所接受治疗的 MM 患者，其中 9 名接受了研究。依鲁替尼在头两个治疗周期（28 天/周期）中每周给予 10mg/kg，随后所有后续周期每两周给予 10mg/kg。共给予 4 种不同的依鲁替尼联合治疗方案：1）依鲁替尼和地塞米松；2）依鲁替尼、来那度胺和地塞米松；3）依鲁替尼、泊马度胺和地塞米松；4）依鲁替尼、卡非佐米、泊马度胺和地塞米松。磷水平在中位数每 13 天测定一次，间隔从每周一次到每月一次，直到给患者开磷补充剂或停止依鲁替尼治疗。我们发现，无论采用何种依鲁替尼联合治疗方案，所有开始依鲁替尼治疗的患者的磷水平均降低，与基线相比降低 12.5%至 44.1%。6 名参与者（67%）在开始依鲁替尼治疗后平均血清磷水平在 2.5mg/dL 或以下。这项回顾性研究表明，接受依鲁替尼治疗的 MM 患者常发生低磷血症。
